3
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Piperacillin/Tazobactam in the Treatment of Lower Respiratory Tract Infections: an Open Non-Comparative and Multicentered TrialFootnote

, , , , &
Pages 197-203 | Published online: 15 Jul 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

J. Sifuentes-Osornio, E. Jakob, L. Clara, R. Durlach, A. Dain, G.M. Ruìz-Palacios, L. Barkan & R. Lamberghini. (1996) Piperacillin/Tazobactam in the Treatment of Hospitalized Patients with Urinary Tract Infections: an Open Non-Comparative and Multicentered Trial. Journal of Chemotherapy 8:2, pages 122-129.
Read now

Articles from other publishers (6)

Josef Yayan, Beniam Ghebremedhin & Kurt Rasche. (2015) No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study. BMC Infectious Diseases 15:1.
Crossref
L. R. Peterson. (2006) Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?. Clinical Infectious Diseases 42:2, pages 224-233.
Crossref
Dieter Adam, Thomas Linglöf, Daniel Floret & Ted Kirsch. (2001) Piperacillin/tazobactam versus cefotaxime plus metronidazole for the treatment of severe intra-abdominal infection in hospitalized pediatric patients. Current Therapeutic Research 62:6, pages 488-502.
Crossref
I. Raad, R. Hachem, H. Hanna, D. Abi-Said, C. Bivins, G. Walsh, J. Thornby, E. Whimbey, A. Huaringa & A. Sukumaran. (2001) Treatment of Nosocomial Postoperative Pneumonia in Cancer Patients: A Prospective Randomized Study. Annals of Surgical Oncology 8:2.
Crossref
Douglas Seaton. 2000. Crofton and Douglas's Respiratory Diseases. Crofton and Douglas's Respiratory Diseases 193 310 .
R. Speich, E. Imhof, M. Vogt, M. Grossenbacher & W. Zimmerli. (1998) Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. European Journal of Clinical Microbiology & Infectious Diseases 17:5, pages 313-317.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.